Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Washington University School of Medicine, St. Louis, Missouri, United States

Survival: 24.0 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: St. Louis, Missouri
Hospital: Washington University School of Medicine
Journal: Link
Date: 9/2010

This phase 2 study involved 79 men with castrate-resistant prostate cancer. The median age of the group was 69 years.

Patients in this study were given a combination of two chemotherapy agents, docetaxel and estramustine, and a biologic therapy agent bevacizumab, which is an antibody the blocks a protein involved in cancer cell growth.

There were 3 deaths related to treatment reported in this study. Causes included infection and thrombosis. Grade 3 and 4 neutropenia, leukopenia, fatigue, and pain were also reported.

The reported median progression-free survival in this study was 8 months. The median overall survival was 24 months.

This study was partially supported by Sanofi-Aventis and Genentech, makers of docetaxel and bevacizumab, respectively.

Correspondence: Dr. Joel Picus; email:

E-mail to a Friend Email Physician More Information